Quick Takeaways
- This page summarizes Arthur S. Kirsch's Form 4 filing for Atea Pharmaceuticals, Inc. (AVIR).
- 1 reported transaction and 1 derivative row are listed below.
- Filing timestamp: 24 Feb 2025, 18:52.
Arthur S. Kirsch - 20 Feb 2025 Form 4 Insider Report for Atea Pharmaceuticals, Inc. (AVIR)
- Role
- Director
- Signature
- /s/ Andrea Corcoran, as Attorney-in-Fact for Arthur S. Kirsch
- Issuer symbol
- AVIR
- Transactions as of
- 20 Feb 2025
- Net transactions value
- $0
- Form type
- 4
- Filing time
- 24 Feb 2025, 18:52:21 UTC
- Previous filing
- 24 Jun 2024
- Next filing
- 20 Jun 2025
- SEC
- View on sec.gov
Quoteable Key Fact
"Arthur S. Kirsch filed Form 4 for Atea Pharmaceuticals, Inc. (AVIR) on 24 Feb 2025."
What Changed
- Previous filing in this sequence was filed on 24 Jun 2024.
- Current net transaction value: $0.
Why This Matters
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Official SEC Source
Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| transaction | AVIR | Stock Option (Right to Buy) | Award | $0 | +164,800 | $0.000000 | 164,800 | 20 Feb 2025 | Common Stock | 164,800 | $3.14 | Direct | F1 |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.
Explanation of Responses:
| Id | Content |
|---|---|
| F1 | The option vests and becomes exercisable in thirty-six (36) equal monthly installments following February 20, 2025 such that the option is fully vested on February 20, 2028. |